Get the Weekly Intelligence Brief — top committee picks every Sunday.
ICLR · NASDAQ · STOCK

ICON Public (ICLR) Stock Analysis

Healthcare Updated October 10, 2026
$164.28
52W $66.57 – $203.91
53/100
$12.57B
38.3
1.24
AI Committee Verdict
Watch
53/100
Conviction: High · 80% agreement · 5 analysts
+13.2%
-4.6%
2.85:1
High

Is ICLR Bullish or Bearish?

Mixed. Innellis AI committee rates ICON Public Limited Company (ICLR) Watch with a composite score of 53/100 , based on 5 analysts with 80% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.42 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.58 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • P/E of 184.8 is expensive by classic value standards — Value
  • ROE of only 0.8% -- cheap may mean cheap for a reason — Value
  • EPS declining -90.8% YoY despite any revenue growth — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
53/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 83%
of 192 Healthcare peers
Value Analyst neutral
44 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 184.8 is expensive by classic value standards
Growth Analyst neutral
48 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -90.8% YoY despite any revenue growth
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.6 to 52.6.

Analyst-level changes:
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
45.7
Neutral
MACD Histogram
-0.644
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$156.70
Resistance
$185.94
Bollinger %B
0.29
Inside Bands
Price vs Moving Averages
EMA 9
$165.39 Below
EMA 21
$166.53 Below
EMA 50
$165.35 Below
EMA 200
$155.32 Above

Fundamental Analysis

Valuation
69
Growth
36
Profitability
13
Financial Health
56
Cash Flow
70
Valuation
P/E Ratio 38.3×
P/B Ratio 1.35×
PEG Ratio -0.68
Dividend Yield 0.00%
52W High $203.91
52W Low $66.57
Quality & Growth
ROE 249.5%
ROA 141.0%
Gross Margin 2184.9%
Operating Margin 1014.9%
Revenue Growth YoY —
Debt / Equity 0.37
AI Fundamental Assessment
P/E ratio of 38.3 (rich relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.5%; Return on assets of 1.4%; Net margin of 4.0%; Gross margin of 21.8%; Current ratio of 0.95 (tight short-term liquidity); Debt-to-equity of 0.37; Free cash flow per share is positive (17.52); Most recent quarter missed estimates by 0.2%; EPS growth accelerating (-0.8% -> +2.4% QoQ); Analyst estimates falling over recent quarters
Get the Full ICLR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime